|
US6908744B1
(en)
*
|
2000-03-14 |
2005-06-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of stimulating cartilage formation
|
|
AU2001283377B2
(en)
*
|
2000-08-14 |
2007-09-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Enhanced homologous recombination mediated by lambda recombination proteins
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6586251B2
(en)
*
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
EP1543110A4
(en)
|
2002-05-17 |
2006-09-06 |
Sinai School Medicine |
POPULATION OF DEFINITIVE ENDODERMIC CELLS AND MESODERMAL
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
AU2003250074B2
(en)
|
2002-07-18 |
2010-09-09 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
EP1539946A4
(en)
*
|
2002-09-09 |
2006-03-15 |
California Inst Of Techn |
METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
|
|
WO2004067725A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of identifying modulators of nmur2-mediated activity
|
|
EP2395017A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
PL2767161T3
(pl)
|
2004-10-19 |
2018-09-28 |
Regeneron Pharmaceuticals, Inc. |
Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
|
|
US20060117396A1
(en)
*
|
2004-11-30 |
2006-06-01 |
Murphy Andrew J |
Assay methods for identifying modulators of OPSDL3 and transgenic knockouts
|
|
EP2125894B1
(en)
|
2007-03-22 |
2018-12-19 |
Biogen MA Inc. |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
|
|
SG182144A1
(en)
|
2007-06-01 |
2012-07-30 |
Omt Inc |
Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
|
|
WO2009076464A2
(en)
*
|
2007-12-10 |
2009-06-18 |
Aliva Biopharmaceuticals, Inc. |
Methods for sequential replacement of targeted region by homologous recombination
|
|
EP2281050B1
(en)
*
|
2008-04-14 |
2014-04-02 |
Sangamo BioSciences, Inc. |
Linear donor constructs for targeted integration
|
|
US20090328240A1
(en)
*
|
2008-06-24 |
2009-12-31 |
Sing George L |
Genetically modified mice as predictors of immune response
|
|
DE102008002715A1
(de)
*
|
2008-06-27 |
2009-12-31 |
Evonik Röhm Gmbh |
2-Hydroxyisobuttersäure produzierende rekombinante Zelle
|
|
WO2010039900A2
(en)
|
2008-09-30 |
2010-04-08 |
Aliva Biopharmaceuticals, Inc. |
Non-human mammals for the production of chimeric antibodies
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
ES2948572T3
(es)
|
2009-07-08 |
2023-09-14 |
Kymab Ltd |
Modelos de roedores y moléculas terapéuticas
|
|
ES3010323T3
(en)
|
2009-10-06 |
2025-04-02 |
Regeneron Pharma |
Genetically modified mice and engraftment
|
|
TR201903376T4
(tr)
|
2009-10-29 |
2019-04-22 |
Regeneron Pharma |
Çok fonksiyonlu alleller.
|
|
MY172472A
(en)
|
2009-12-10 |
2019-11-26 |
Regeneron Pharma |
Mice that make heavy chain antibodies
|
|
JP5595517B2
(ja)
|
2009-12-21 |
2014-09-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ＦｃγＲマウス
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
ES2547142T5
(es)
|
2010-02-08 |
2021-12-09 |
Regeneron Pharma |
Cadena ligera común de ratón
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
KR20210010942A
(ko)
|
2010-03-31 |
2021-01-28 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
|
MY195217A
(en)
|
2010-06-22 |
2023-01-11 |
Regeneron Pharma |
MICE Expressing An Immunoglobulin Hybrid Light Chain
|
|
EP2597945B1
(en)
|
2010-07-26 |
2020-07-22 |
Trianni, Inc. |
Transgenic animals and methods of use
|
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
IL315833A
(en)
|
2010-08-02 |
2024-11-01 |
Regeneron Pharma |
Mice producing binding proteins containing VL regions
|
|
EP2638155A1
(en)
|
2010-11-08 |
2013-09-18 |
Kymab Limited |
Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
|
|
CA3027071A1
(en)
|
2011-01-14 |
2013-07-19 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
KR102714361B1
(ko)
|
2011-02-15 |
2024-10-11 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화된 ｍ－ｃｓｆ 마우스
|
|
HUE024534T2
(hu)
|
2011-02-25 |
2016-01-28 |
Regeneron Pharma |
ADAM6 egerek
|
|
US10920242B2
(en)
|
2011-02-25 |
2021-02-16 |
Recombinetics, Inc. |
Non-meiotic allele introgression
|
|
DK2527842T3
(da)
|
2011-05-12 |
2013-09-08 |
Regeneron Pharma |
Neuropeptidfrisætningsanalyse til natriumkanaler
|
|
IL273982B2
(en)
|
2011-08-05 |
2023-03-01 |
Regeneron Pharma |
Humanized mice possess a universal light chain
|
|
WO2013041845A2
(en)
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Animals, repertoires & methods
|
|
EP2757875B2
(en)
|
2011-09-19 |
2023-03-22 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
US10246509B2
(en)
|
2011-10-17 |
2019-04-02 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
KR101926442B1
(ko)
|
2011-10-28 |
2018-12-12 |
리제너론 파아마슈티컬스, 인크. |
키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스
|
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
SMT202100243T1
(it)
|
2011-10-28 |
2021-05-07 |
Regeneron Pharma |
Topi con recettori delle cellule t geneticamente modificati
|
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
DK2770821T3
(da)
|
2011-10-28 |
2017-11-27 |
Regeneron Pharma |
Genetisk modificerede major histocompatibility-kompleks-mus
|
|
US9381518B2
(en)
|
2011-10-31 |
2016-07-05 |
Merck Sharp & Dohme Corp. |
Nano-suspension process
|
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
SG11201403326VA
(en)
|
2011-12-20 |
2014-07-30 |
Regeneron Pharma |
Humanized light chain mice
|
|
WO2013116609A1
(en)
|
2012-02-01 |
2013-08-08 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents that express heavy chains containing vl domains
|
|
EP3165086A1
(en)
|
2012-03-06 |
2017-05-10 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
AU2013204581B2
(en)
|
2012-03-16 |
2015-06-25 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing pH-sensitive immunoglobulin sequences
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
RU2664473C2
(ru)
|
2012-03-16 |
2018-08-17 |
Регенерон Фармасьютикалз, Инк. |
ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
|
|
EP2825036B1
(en)
|
2012-03-16 |
2018-05-02 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
WO2013144567A1
(en)
|
2012-03-28 |
2013-10-03 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
|
|
SG11201406547YA
(en)
|
2012-04-25 |
2014-11-27 |
Regeneron Pharma |
Nuclease-mediated targeting with large targeting vectors
|
|
PT3597037T
(pt)
|
2012-06-12 |
2021-06-01 |
Regeneron Pharma |
Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
|
|
AR091482A1
(es)
*
|
2012-06-21 |
2015-02-04 |
Recombinetics Inc |
Celulas modificadas geneticamente y metodos par su obtencion
|
|
KR102355959B1
(ko)
|
2012-08-23 |
2022-01-27 |
어젠시스 인코포레이티드 |
158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
|
|
ES2702315T3
(es)
|
2012-08-24 |
2019-02-28 |
Univ California |
Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
|
|
KR102473555B1
(ko)
|
2012-09-07 |
2022-12-05 |
예일 유니버시티 |
유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
|
|
UA118090C2
(uk)
*
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
IL311744B2
(en)
|
2012-11-05 |
2025-10-01 |
Regeneron Pharma |
Genetically modified non-human animals and methods of using them
|
|
SMT201800435T1
(it)
|
2013-02-20 |
2018-09-13 |
Regeneron Pharma |
Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate
|
|
CN109913495B
(zh)
|
2013-02-20 |
2022-11-25 |
瑞泽恩制药公司 |
大鼠的遗传修饰
|
|
LT2958938T
(lt)
|
2013-02-20 |
2019-07-25 |
Regeneron Pharmaceuticals, Inc. |
Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius
|
|
EP2958937B1
(en)
|
2013-02-22 |
2018-08-15 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized major histocompatibility complex
|
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
|
WO2014164640A1
(en)
|
2013-03-11 |
2014-10-09 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
|
|
EP4249507A3
(en)
|
2013-03-11 |
2023-12-27 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
|
|
CN105189545A
(zh)
|
2013-03-13 |
2015-12-23 |
瑞泽恩制药公司 |
常见轻链小鼠
|
|
AU2014244020B2
(en)
|
2013-03-13 |
2020-06-04 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
SG10201808935WA
(en)
*
|
2013-04-16 |
2018-11-29 |
Regeneron Pharma |
Targeted modification of rat genome
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
CN105722534B
(zh)
|
2013-08-01 |
2019-05-31 |
艾更斯司股份有限公司 |
结合cd37蛋白的抗体药物偶联物(adc)
|
|
AU2014305873B2
(en)
|
2013-08-07 |
2017-08-31 |
President And Fellows Of Harvard College |
LincRNA-deficient non-human animals
|
|
RU2019121863A
(ru)
|
2013-09-18 |
2019-08-29 |
Регенерон Фармасьютикалз, Инк. |
Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
|
|
PT4269430T
(pt)
|
2013-09-23 |
2025-08-06 |
Regeneron Pharma |
Animais não-humanos com um gene humanizado de proteína reguladora de sinal
|
|
ES2993142T3
(en)
|
2013-10-01 |
2024-12-23 |
Kymab Ltd |
Animal models and therapeutic molecules
|
|
EP3071025B1
(en)
|
2013-11-19 |
2018-10-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized a proliferation-inducing ligand gene
|
|
MX356809B
(es)
|
2013-11-19 |
2018-06-13 |
Regeneron Pharma |
Animales no humanos que tienen un gen del factor activador de celulas b.
|
|
JP6174811B2
(ja)
*
|
2013-12-11 |
2017-08-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ゲノムの標的改変のための方法及び組成物
|
|
SMT201800653T1
(it)
|
2013-12-11 |
2019-01-11 |
Regeneron Pharma |
Metodi e composizioni per la modificazione indirizzata a bersaglio di un genoma
|
|
US11160879B2
(en)
|
2014-01-15 |
2021-11-02 |
Masamichi Yamamoto |
Transgenic animal for visualization of ATP and use thereof
|
|
TWI681969B
(zh)
*
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
ES2762640T3
(es)
|
2014-03-21 |
2020-05-25 |
Regeneron Pharma |
Proteínas VL de unión a antígeno que exhiben diferentes características de unión
|
|
BR112016021572A2
(pt)
|
2014-03-21 |
2017-10-03 |
Regeneron Pharma |
Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
|
|
KR20250096864A
(ko)
|
2014-05-19 |
2025-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
인간 epo를 발현하는 유전자 변형된 비-인간 동물
|
|
US9497945B2
(en)
|
2014-05-30 |
2016-11-22 |
Regeneron Pharmaceuticals, Inc. |
Humanized dipeptidyl peptidase IV (DPP4) animals
|
|
MX385689B
(es)
|
2014-06-06 |
2025-03-18 |
Regeneron Pharma |
Métodos y composiciones para modificar un locus dirigido.
|
|
CN106604635B
(zh)
|
2014-06-19 |
2020-01-14 |
瑞泽恩制药公司 |
具有人源化程序性细胞死亡1基因的非人动物
|
|
US9738897B2
(en)
|
2014-06-23 |
2017-08-22 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated DNA assembly
|
|
WO2015200805A2
(en)
|
2014-06-26 |
2015-12-30 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
|
RU2017113134A
(ru)
|
2014-09-19 |
2018-10-19 |
Регенерон Фармасьютикалз, Инк. |
Химерные антигенные рецепторы
|
|
EP3561052A1
(en)
|
2014-10-15 |
2019-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
|
ES2731437T3
(es)
|
2014-11-21 |
2019-11-15 |
Regeneron Pharma |
Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
|
|
DK3223605T3
(da)
|
2014-11-24 |
2020-11-16 |
Regeneron Pharma |
Ikke-humane dyr, der eksprimerer humaniseret cd3-kompleks
|
|
EP3086637B1
(en)
|
2014-12-05 |
2019-01-02 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized cluster of differentiation 47 gene
|
|
MX2017007636A
(es)
|
2014-12-09 |
2018-03-28 |
Regeneron Pharma |
Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
|
|
MX388784B
(es)
|
2014-12-19 |
2025-03-20 |
Regeneron Pharma |
Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
|
|
TWI719967B
(zh)
|
2015-03-09 |
2021-03-01 |
美商艾澤西公司 |
結合至ｆｌｔ３蛋白之抗體藥物結合物（ａｄｃ）
|
|
IL274285B
(en)
|
2015-03-16 |
2022-07-01 |
Regeneron Pharma |
Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
KR20240132525A
(ko)
|
2015-04-06 |
2024-09-03 |
리제너론 파아마슈티컬스, 인크. |
비인간 동물에서의 인간화 t 세포 매개 면역반응
|
|
CN107896479B
(zh)
|
2015-04-13 |
2021-07-13 |
再生元制药公司 |
人源化SIRPα-IL15敲入小鼠及其使用方法
|
|
JP6913030B2
(ja)
|
2015-05-18 |
2021-08-04 |
アジェンシス，インコーポレイテッド |
Ａｘｌタンパク質に結合する抗体
|
|
US10395759B2
(en)
|
2015-05-18 |
2019-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for copy number variant detection
|
|
WO2016187354A1
(en)
|
2015-05-18 |
2016-11-24 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
KR102377189B1
(ko)
|
2015-05-29 |
2022-03-22 |
리제너론 파마슈티칼스 인코포레이티드 |
C9orf72 유전자좌에서 파괴를 갖는 비-인간 동물
|
|
EP3344034A1
(en)
|
2015-09-02 |
2018-07-11 |
Regeneron Pharmaceuticals, Inc. |
Rodent model of prostate cancer
|
|
TWI752920B
(zh)
|
2015-10-12 |
2022-01-21 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
AU2016358101B2
(en)
|
2015-11-20 |
2022-12-01 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized Lymphocyte-activation gene 3
|
|
RU2752498C2
(ru)
*
|
2015-11-24 |
2021-07-28 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Стабильные клеточные линии для продуцирования ретровирусов
|
|
US10450574B2
(en)
*
|
2015-11-24 |
2019-10-22 |
Glaxosmithkline Intellectual Property Development Limited |
Transient transfection method for retroviral production
|
|
EP3384030A4
(en)
|
2015-12-03 |
2019-07-03 |
Trianni, Inc. |
IMPROVED IMMUNOGLULINIVITY
|
|
IL302725A
(en)
|
2016-01-13 |
2023-07-01 |
Regeneron Pharma |
Rodents having an engineered heavy chain diversity region
|
|
US20170218398A1
(en)
*
|
2016-01-30 |
2017-08-03 |
Markus Alexander Brown |
Method to selectively target cancerous cells for genetic manipulation
|
|
KR102487839B1
(ko)
*
|
2016-02-04 |
2023-01-12 |
리제너론 파마슈티칼스 인코포레이티드 |
조작된 angptl8 유전자를 갖는 비인간 동물
|
|
WO2017136734A1
(en)
|
2016-02-04 |
2017-08-10 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
|
AU2017218149B2
(en)
|
2016-02-12 |
2020-09-03 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for detection of abnormal karyotypes
|
|
SG11201806427WA
(en)
|
2016-02-16 |
2018-08-30 |
Regeneron Pharma |
Non-human animals having a mutant kynureninase gene
|
|
SG10202001578RA
(en)
|
2016-02-29 |
2020-04-29 |
Regeneron Pharma |
Rodents having a humanized tmprss gene
|
|
JP2019515369A
(ja)
|
2016-03-29 |
2019-06-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
遺伝的バリアント−表現型解析システムおよび使用方法
|
|
MX2018014172A
(es)
|
2016-05-20 |
2019-08-22 |
Regeneron Pharma |
Métodos para romper la tolerancia inmunológica usando múltiples arn guías.
|
|
CN109640644B
(zh)
|
2016-06-03 |
2021-10-26 |
瑞泽恩制药公司 |
表达外源末端脱氧核苷酸转移酶的非人动物
|
|
MX2018016330A
(es)
|
2016-06-27 |
2020-02-17 |
Univ California |
Combinaciones para tratamiento del cáncer.
|
|
EP3476865B1
(en)
|
2016-06-28 |
2023-09-13 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Method for constructing pd-1 gene-modified humanized animal model and use thereof
|
|
US10548302B2
(en)
|
2016-07-29 |
2020-02-04 |
Regeneron Pharmaceuticals, Inc. |
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
|
|
EP3518667B1
(en)
*
|
2016-09-30 |
2024-10-30 |
Regeneron Pharmaceuticals, Inc. |
Rodents having a hexanucleotide repeat expansion in a c9orf72 locus
|
|
CA3038720A1
(en)
|
2016-11-04 |
2018-07-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having an engineered immunoglobulin lambda light chain locus
|
|
CN118140872A
(zh)
|
2017-01-19 |
2024-06-07 |
欧莫诺艾比公司 |
来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
|
|
JP2020508073A
(ja)
|
2017-02-27 |
2020-03-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
網膜分離症の非ヒト動物モデル
|
|
JP2020533957A
(ja)
|
2017-07-31 |
2020-11-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｃｒｉｓｐｒリポーター非ヒト動物およびその使用
|
|
WO2019028032A1
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF
|
|
EP3585162B1
(en)
|
2017-09-29 |
2023-08-30 |
Regeneron Pharmaceuticals, Inc. |
Rodents comprising a humanized ttr locus and methods of use
|
|
SG11202002002XA
(en)
|
2017-09-29 |
2020-04-29 |
Regeneron Pharma |
Non-human animals expressing humanized c1q complex
|
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
|
|
CN109666701B
(zh)
*
|
2017-10-13 |
2021-08-24 |
百奥赛图(北京)医药科技股份有限公司 |
一种pd-1基因修饰人源化动物模型的构建方法及其应用
|
|
CA3076377A1
(en)
|
2017-11-30 |
2019-06-06 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized trkb locus
|
|
SG11202003044SA
(en)
|
2017-12-05 |
2020-04-29 |
Regeneron Pharma |
Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
|
|
CN116349651A
(zh)
|
2018-03-19 |
2023-06-30 |
瑞泽恩制药公司 |
使用crispr/cas系统对动物进行转录调制
|
|
CA3093850A1
(en)
|
2018-03-26 |
2019-10-03 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents for testing therapeutic agents
|
|
CA3094400A1
(en)
|
2018-04-06 |
2019-10-10 |
Regeneron Pharmaceuticals, Inc. |
A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
|
|
EP3811364A1
(en)
|
2018-06-01 |
2021-04-28 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for sparse vector-based matrix transformations
|
|
IL318469A
(en)
|
2018-06-14 |
2025-03-01 |
Regeneron Pharma |
Non-human animals capable of reorganizing transgenic DH-DH, and their uses
|
|
SMT202400300T1
(it)
|
2018-07-16 |
2024-09-16 |
Regeneron Pharma |
Modelli di roditori della sindrome ditra e loro utilizzo
|
|
CN109504708A
(zh)
*
|
2018-12-03 |
2019-03-22 |
江苏集萃药康生物科技有限公司 |
一种筛选标记自我删除的基因打靶载体及方法
|
|
CN113423831B
(zh)
|
2018-12-20 |
2023-03-10 |
瑞泽恩制药公司 |
核酸酶介导的重复扩增
|
|
WO2020152607A1
(en)
|
2019-01-22 |
2020-07-30 |
St. Jude Children's Research Hospital |
Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
|
|
EP3927832A4
(en)
*
|
2019-02-18 |
2022-11-30 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
|
|
US11464217B2
(en)
|
2019-02-22 |
2022-10-11 |
Regeneron Pharmaceuticals, Inc. |
Rodents having genetically modified sodium channels and methods of use thereof
|
|
CN117178959A
(zh)
|
2019-04-04 |
2023-12-08 |
瑞泽恩制药公司 |
包括人源化凝血因子12基因座的非人动物
|
|
IL286917B
(en)
|
2019-04-04 |
2022-09-01 |
Regeneron Pharma |
Methods for scarless introduction of targeted modifications into targeting vectors
|
|
KR20210153092A
(ko)
|
2019-04-15 |
2021-12-16 |
퀴셀 세라퓨틱스 엘엘씨 |
암 치료에 사용하기 위한, 마스킹된 유형 i 인터페론(ifna 및 ifnb) 및 종양 항원에 대한 항체를 포함하는 융합 단백질 조성물
|
|
AU2020286382A1
(en)
|
2019-06-04 |
2021-11-04 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
|
SG11202111258TA
(en)
|
2019-06-05 |
2021-11-29 |
Regeneron Pharma |
Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
|
|
MX2021015122A
(es)
|
2019-06-07 |
2022-04-06 |
Regeneron Pharma |
Animales no humanos que comprenden un locus de albumina humanizado.
|
|
CA3139469A1
(en)
|
2019-06-27 |
2020-12-30 |
Aarti Sharma-Kanning |
Modeling tdp-43 proteinopathy
|
|
SMT202400527T1
(it)
|
2019-07-01 |
2025-01-14 |
Tonix Pharma Ltd |
Anticorpi anti-cd154 e loro usi
|
|
CA3154710A1
(en)
|
2019-10-04 |
2021-04-08 |
TAE Life Sciences |
Antibody compositions comprising fc mutations and site-specific conjugation properties
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
WO2021154791A1
(en)
|
2020-01-28 |
2021-08-05 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized pnpla3 locus and methods of use
|
|
EP4099821A1
(en)
|
2020-02-07 |
2022-12-14 |
Regeneron Pharmaceuticals, Inc. |
<smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
|
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
AU2021261267A1
(en)
|
2020-04-21 |
2022-09-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized Cxcl13 gene
|
|
IL298632A
(en)
|
2020-06-02 |
2023-01-01 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Non-human animals genetically modified with a common light chain immunoglobulin locus
|
|
RU2751237C1
(ru)
*
|
2020-06-10 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
|
KR20230024822A
(ko)
|
2020-06-25 |
2023-02-21 |
주식회사 휴맵 |
이형접합성 형질전환 동물
|
|
TW202229328A
(zh)
|
2020-09-11 |
2022-08-01 |
美商再生元醫藥公司 |
抗原特異性抗體之鑑定及產生
|
|
IL315694A
(en)
|
2020-10-01 |
2024-11-01 |
Regeneron Pharma |
Rodent animals expressing human cr1
|
|
US12012441B2
(en)
|
2020-10-26 |
2024-06-18 |
Neptune Biosciences Llc |
Engineered human IL-21 cytokines and methods for using the same
|
|
JP2024500399A
(ja)
|
2020-12-16 |
2024-01-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化Ｆｃアルファ受容体を発現するマウス
|
|
CA3171455A1
(en)
|
2020-12-21 |
2022-06-30 |
Yajun Tang |
Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene
|
|
IL303868A
(en)
|
2020-12-23 |
2023-08-01 |
Regeneron Pharma |
Nucleic acids encoding anchor-modified antibodies and uses thereof
|
|
EP4274587A1
(en)
|
2021-01-06 |
2023-11-15 |
Tonix Pharma Limited |
Methods of inducing immune tolerance with modified anti-cd154 antibodies
|
|
CN118511853A
(zh)
|
2021-03-31 |
2024-08-20 |
瑞泽恩制药公司 |
包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
|
|
US20240199725A1
(en)
|
2021-04-16 |
2024-06-20 |
Korea University Research And Business Foundation |
Human antibody targeting covid-19 virus
|
|
JP2024523290A
(ja)
|
2021-06-18 |
2024-06-28 |
ナミ セラピューティクス， インコーポレイテッド |
がんの処置およびその方法における使用のための、マスクされたＩ型インターフェロン（ＩＦＮαおよびＩＦＮβ）を含む融合タンパク質組成物
|
|
CN118251491A
(zh)
|
2021-10-28 |
2024-06-25 |
瑞泽恩制药公司 |
用于敲除C5的CRISPR/Cas相关方法及组合物
|
|
CN118632622A
(zh)
|
2021-12-08 |
2024-09-10 |
瑞泽恩制药公司 |
突变型肌纤蛋白疾病模型及其用途
|
|
WO2023122506A1
(en)
|
2021-12-20 |
2023-06-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
|
EP4475671A1
(en)
|
2022-02-07 |
2024-12-18 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
EP4476245A1
(en)
|
2022-02-11 |
2024-12-18 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for screening 4r tau targeting agents
|
|
EP4514125A1
(en)
|
2022-04-26 |
2025-03-05 |
Regeneron Pharmaceuticals, Inc. |
A rodent model of fibrodysplasia ossificans progressiva
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
WO2023235677A1
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Animal model of tdp-43 proteinopathy
|
|
US20230417899A1
(en)
|
2022-06-27 |
2023-12-28 |
Oshkosh Corporation |
Position tracking for a lift device
|
|
KR20250040674A
(ko)
|
2022-07-19 |
2025-03-24 |
리제너론 파마슈티칼스 인코포레이티드 |
유전적으로 변형된 동물 모델 및 인간 면역 시스템을 모델링하는데 있어서 그것의 용도
|
|
AU2023347224A1
(en)
|
2022-09-22 |
2025-03-20 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice expressing components of human cellular immune system
|
|
US20240224964A9
(en)
|
2022-09-29 |
2024-07-11 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
|
WO2024163650A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Animals comprising a modified klhdc7b locus
|
|
WO2024258743A1
(en)
|
2023-06-13 |
2024-12-19 |
Adcentrx Therapeutics, Inc. |
Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
|
|
AU2024304358A1
(en)
|
2023-06-16 |
2025-11-06 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2025122669A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized complement factor b gene
|
|
US20250255282A1
(en)
|
2024-02-08 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2025212991A1
(en)
|
2024-04-05 |
2025-10-09 |
Regeneron Pharmaceuticals, Inc. |
Rodent models of disease
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025250495A1
(en)
|
2024-05-28 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
|